Evidence map›Paper›PMID 27322245›Full record

ArticleInternational journal of molecular sciences2016

Next Generation Sequencing Approach in a Prenatal Case of Cardio-Facio-Cutaneus Syndrome.

Mafalda Mucciolo, Claudio Dello Russo, Laura D'Emidio, Alvaro Mesoraca, Claudio Giorlandino

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Recombinant GH treatment in a case of Costello syndrome with a 5-year follow-up.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mafalda MuccioloDepartment of Human Genetics, Altamedica Fetal-Maternal Medical Centre, 00198 Rome, Italy. mafalda.mucciolo@artemisia.it.
Claudio Dello RussoDepartment of Human Genetics, Altamedica Fetal-Maternal Medical Centre, 00198 Rome, Italy. claudio.dellorusso@artemisia.it.
Laura D'EmidioDepartment of Prenatal Diagnosis, Altamedica Fetal-Maternal Medical Centre, 00198 Rome, Italy. laura.demidio@artemisia.it.
Alvaro MesoracaDepartment of Human Genetics, Altamedica Fetal-Maternal Medical Centre, 00198 Rome, Italy. alvaro.mesoraca@artemisia.it.
Claudio GiorlandinoDepartment of Prenatal Diagnosis, Altamedica Fetal-Maternal Medical Centre, 00198 Rome, Italy. claudio.giorlandino@artemisia.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiofaciocutaneous syndrome (CFCS) belongs to a group of developmental disorders due to defects in the Ras/Mitogen-Activated Protein Kinase (RAS/MAPK) signaling pathway named RASophaties. While postnatal presentation of these disorders is well known, the prenatal and neonatal characteristics are less recognized. Noonan syndrome, Costello syndrome, and CFCS diagnosis should be considered in pregnancies with a normal karyotype and in the case of ultrasound findings such as increased nuchal translucency, polyhydramnios, macrosomia and cardiac defect. Because all the RASopathies share similar clinical features, their molecular characterization is complex, time consuming and expensive. Here we report a case of CFCS prenatally diagnosed through Next Generation Prenatal Diagnosis (NGPD), a new targeted approach that allows us to concurrently investigate all the genes involved in the RASophaties.

Indexed as

BRAFcardiofaciocutaneousnext generation sequencingNGPDRASophaties

Identifiers

PMID27322245
PMCPMC4926485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.